You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

PD-L1/VEGF

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC Trial (PM8002, Placebo, Carboplatin)

Not yet recruiting
  • NSCLC
  • (no location specified)
Feb 23, 2023

SCLC Trial (PM8002, Platinum, Atezolizumab)

Not yet recruiting
  • SCLC
  • (no location specified)
May 4, 2023

Tumors Malignant Trial in Shanghai (B1962)

Not yet recruiting
  • Neoplasms Malignant
  • Shanghai, Shanghai, China
    Shanghai Pulmonary Hospital
Dec 13, 2022

Hepatocellular Carcinoma Trial (PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, TACE)

Recruiting
  • Hepatocellular Carcinoma
  • PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab
  • TACE
  • Nanjing, China
  • +1 more
Dec 28, 2022

Hepatocellular Carcinoma Trial (PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, TACE)

Recruiting
  • Hepatocellular Carcinoma
  • PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab
  • TACE
  • Nanjing, China
  • +1 more
Dec 28, 2022

Malignant Tumor Trial in Shanghai (PM8002)

Recruiting
  • Malignant Neoplasm
  • Shanghai, Shanghai, China
    Shanghai Orient Hospital
Jun 25, 2023

Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for

Recruiting
  • Hepatocellular Carcinoma Non-resectable
  • HAIC
  • +8 more
  • Quanzhou, Fujian, China
  • +1 more
Jan 26, 2023

Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for

Recruiting
  • Hepatocellular Carcinoma Non-resectable
  • TACE
  • +8 more
  • Quanzhou, Fujian, China
  • +3 more
Jan 29, 2023

Clinical Stage III Cutaneous Melanoma AJCC v8, Stage IV Melanoma, Unresectable Stage III Cutaneous Melanoma Trial in Boston

Recruiting
  • Clinical Stage III Cutaneous Melanoma AJCC v8
  • +3 more
  • Boston, Massachusetts
  • +2 more
Sep 17, 2022

Advanced Solid Tumors Trial in China (IMM2510)

Recruiting
  • Advanced Solid Tumors
  • Luoyang, Henan, China
  • +3 more
Jul 25, 2023

TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular

Recruiting
  • Hepatocellular Carcinoma
    • Nanjing, Jiangsu, China
      Zhongda Hospital, Southeast University
    Mar 4, 2022

    Lung Cancer Trial (Centipeda minima+PD-1/PD-L1 inhibitor, PD-1/PD-L1 inhibitor)

    Not yet recruiting
    • Lung Cancer
    • Centipeda minima+PD-1/PD-L1 inhibitor
    • PD-1/PD-L1 inhibitor
    • (no location specified)
    Feb 17, 2023

    Advanced Solid Tumor Trial in Beijing (Inosine 0.2g orally 3 times/day, PD-1/PD-L1 inhibitor ,chemo/targeting)

    Completed
    • Advanced Solid Tumor
    • Inosine 0.2g orally 3 times/day
    • PD-1/PD-L1 inhibitor ,chemotherapy/targeting
    • Beijing, Beijing, China
      Qin li
    Mar 30, 2023

    Digestive System Cancers Trial in Beijing (KN046, Regorafenib, Apatinib)

    Recruiting
    • Digestive System Cancers
    • Beijing, China
      Peking University Cancer Hospital
    Oct 25, 2023

    Combined Statin and PD-1/PD-L1 Inhibitors in Treating Non-small

    Recruiting
    • Lung Cancer
    • Yiwu, Zhejiang, China
      The Fourth Affiliated Hospital of Zhejiang University
    Dec 16, 2022

    High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD-L1

    Suspended
    • NSCLC Stage IV
    • NSCLC, Stage IIIC
    • Primary Immune Response (PIR) test by Biodesix, Inc.
    • San Carlos, California
    • +1 more
    Jan 26, 2023

    SCLC, Extensive Stage Trial in Shanghai (AK112, Etoposide, Carboplatin)

    Recruiting
    • SCLC, Extensive Stage
    • Shanghai, Shanghai, China
      Shun Lu
    Oct 12, 2022

    Glioblastoma Trial (Bevacizumab, PD-L1 t-haNK, N-803)

    Not yet recruiting
    • Glioblastoma
    • (no location specified)
    Sep 25, 2023

    Advanced Non Small Cell Lung Cancer Trial ([18F]F-AraG)

    Not yet recruiting
    • Advanced Non Small Cell Lung Cancer
    • (no location specified)
    Oct 24, 2023

    Advanced Lung Carcinoma Trial in Beijing (LK101 injection (personlized neoantigen pulsed DC vaccine ), Pembrolizumab,

    Recruiting
    • Advanced Lung Carcinoma
    • LK101 injection (personlized neoantigen pulsed DC vaccine )
    • +2 more
    • Beijing, Beijing, China
      Cancer hospital Chinese Academy of Medical Sciences
    May 23, 2023

    Advanced Solid Tumor, Refractory Tumor Trial in Suzhou (Thymalfasin, Radiotherapy, PD-1/PD-L1 inhibitor)

    Recruiting
    • Advanced Solid Tumor
    • Refractory Tumor
    • Suzhou, China
      The Second Affiliated Hospital of SchoowUniversity
    Mar 29, 2023

    Biliary Tract Cancer, Candonilimab, Claudin 18.2 Trial in Shanghai (cardonilizumab, LM-302)

    Recruiting
    • Biliary Tract Cancer
    • +2 more
    • Shanghai, China
      Zhongshan hospital, Fudan University
    Aug 12, 2023

    Advanced Solid Tumor Trial in Chengdu (Dual-targeting CLDN18.2 and PD-L1 CAR-T cells)

    Not yet recruiting
    • Advanced Solid Tumor
    • Dual-targeting CLDN18.2 and PD-L1 CAR-T cells
    • Chengdu, Sichuan, China
      West China Hospital, Sichuan University
    Oct 9, 2023

    Advanced Solid Tumors, Metastatic Solid Tumors Trial in Lyon (NP137, anti-PD-1/PD-L1)

    Recruiting
    • Advanced Solid Tumors
    • Metastatic Solid Tumors
    • Lyon, France
      Centre Léon Bérard
    Nov 30, 2022

    Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression = 1% and an STK11

    Recruiting
    • Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation
    • Montpellier, France
    • +7 more
    Dec 19, 2022